Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Diabetes and arterial hypertension].

C Dal Palù1

  • 1Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi Via Giustiniani, 2 35126 Padova.

Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology
|January 5, 2002
PubMed
Summary

Type II diabetes and hypertension often coexist with obesity, significantly increasing cardiovascular risks. Aggressive treatment, including ACE-inhibitors, is crucial for managing blood pressure and improving patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Hemodynamic modifications from nicotinic acid in hypertension].

Folia cardiologica·2014
Same author

[Aspects of precordial leads; rSŕ morphology in V1 lead].

Folia cardiologica·2014
Same author

[Arterial tension reaction. I. postural, cold pressor, amyl nitrite and sedation tests].

Folia cardiologica·2014
Same author

[Arterial tension reaction. II. Adrenalin, pituitrin, aminophylline, acetylcholine and nicotinic acid tests].

Folia cardiologica·2014
Same author

Hepatic Clearance and Lm of Galactose in Normal and Cirrhotic Subjects.

Postgraduate medical journal·2011
Same author

The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness.

Journal of hypertension·1998

Area of Science:

  • Endocrinology and Cardiovascular Medicine
  • Metabolic Syndrome Research

Context:

  • Type II diabetes and hypertension are prevalent comorbidities in adults, particularly in developed nations.
  • Obesity exacerbates the cardiovascular risks associated with diabetes and hypertension, creating a significant public health challenge.
  • The co-occurrence of these conditions elevates the risk of cardiovascular complications far beyond that of isolated hypertension.

Purpose:

  • To highlight the increased cardiovascular risk in patients with coexisting Type II diabetes, hypertension, and obesity.
  • To discuss the contributing factors to this elevated risk, including hyperglycemia, metabolic syndrome (Syndrome X), and hyperinsulinemia.
  • To emphasize the necessity of aggressive non-pharmacological and pharmacological therapeutic strategies.

Summary:

  • The combination of Type II diabetes, hypertension, and obesity leads to a substantially higher risk of cardiovascular complications.
  • Factors such as hyperglycemia, metabolic syndrome (hyperlipemia, hyperuricemia, thrombophilia, altered Na(+)-H+ membrane exchanges), and hyperinsulinemia contribute to atherosclerosis and clinical events.
  • Effective management necessitates aggressive therapeutic approaches, often involving multiple antihypertensive medications.
  • Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers are recommended, especially for hypertensive patients with diabetes and proteinuria.

Impact:

  • Aggressive blood pressure control is universally recognized as the most effective strategy for improving prognosis in this high-risk population.
  • Understanding the interplay between diabetes, hypertension, obesity, and metabolic factors is key to developing targeted interventions.
  • The findings underscore the importance of comprehensive management strategies to mitigate cardiovascular events in patients with these comorbidities.

Related Experiment Videos